AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
S
ShionogiJapanese pharmaceutical company developing prescription drugs, infectious disease therapies, and specialty medicines, including a former sleep apnea drug joint venture with Apnimed.
2 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
Attovia TherapeuticsShionogi
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Attovia TherapeuticsShionogi
Biotech
Sector
Biotech
2023
Founded
1878
San Carlos, CA
HQ
Osaka, Japan
Public (ATTO)
Status
Public (4507.T)
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Shionogi investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Shionogi.